Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Press Releases
1675 Articles Available
1
70
Can't find what you're looking for? Try our
advanced search
.
Generics
Teva Announces Launch of a Generic Version of VESIcare® (solifenacin succinate) Tablets in the United States
PR-M04-19-NI-072
Launch
Grant Thornton launches EU MDR and IVDR tools for medical device and diagnostics industry
PR-M04-19-NI-073
Appointment
Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer
PR-M04-19-NI-071
Research
Overlooked Molecular Machine in Cell Nucleus May Hold Key to Treating Aggressive Leukemia
CRISPR
Researchers Use Gene Editing with CRISPR to Treat Lethal Lung Diseases before Birth
PR-M04-19-NI-069
Launch
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida
PR-M04-19-NI-068
Clinical Data
United BioPharma Announces Publication of Breakthrough HIV Clinical Trial Data in the New England Journal of Medicine
PR-M04-19-NI-066
Market Prediction
The Heart Valve Repair and Replacement Devices Market Will Register a CAGR of Nearly 16% by 2023
PR-M04-19-NI-067
Strategic Partnership
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs
PR-M04-19-NI-065
Adherence
Common Sensing Gocap Reveals Insulin Adherence Effects on Glycemic Control
PR-M04-19-NI-064
Assay
Ortho's VITROS® High Sensitivity Troponin I Assay for the Diagnosis of Heart Attack Now CE Marked, Available in EU Countries
PR-M04-19-NI-063
Oncology
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer
PR-M04-19-NI-062
Microbiome
Zymo Research Corp. Partners with the UCI Microbiome Initiative
PR-M04-19-NI-061
FDA Action
FDA Orders Manufacturers of Surgical Mesh Intended for Transvaginal Repair of Pelvic Organ Prolapse to Stop Selling All Devices
PR-M04-19-NI-060
FDA Statement
FDA Statement from Deputy Commissioner On New Steps to Protect Consumers from Unlawful Ingredients in Dietary Supplements
PR-M04-19-NI-059
Antibiotic Resistant
FIU Scientists Discover New Arsenic-Based Broad-Spectrum Antibiotic
PR-M04-19-NI-058
Stability
Alchem International Solves Stability Dilemma for Micronized Digoxin and Files Patent for Novel Production Process
PR-M04-19-NI-055
Stem Cells
To Protect Stem Cells, Plants Have Diverse Genetic Backup Plans
PR-M04-19-NI-056
Drug Development
EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
PR-M04-19-NI-054
FDA Acceptance
Novartis Announces FDA Filing Acceptance and Priority Review of Brolucizumab (RTH258) for Patients with Wet AMD
PR-M04-19-NI-053
Capacity Expansion
Biotechpharma to Expand Process Development and GMP Manufacturing Capacity to 5,000 L
PR-M04-19-NI-057
Transaction
Immunic Therapeutics and Vital Therapies Complete Transaction Creating Nasdaq-Listed Company Targeting Chronic Inflammatory and Autoimmune Diseases
PR-M04-19-NI-052
Bone Graft
Collagen Matrix, Inc. Receives FDA 510(k) Clearance of a Bioactive Moldable Bone Graft Matrix
PR-M04-19-NI-051
FDA Approval
FDA Approves First Targeted Therapy for Metastatic Bladder Cancer
PR-M04-19-NI-050
1
70
»
